Skip to main content

Table 1 Clinical characteristics of patients ( n= 120) in whom local-regional progression-free survival was assessed

From: Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Variable <63 Gy ≥63 Gy χ 2 p
Gender     
  Male 33 53 2.387 0.122
  Female 8 26
Age (years)     
  <65 27 55 0.177 0.674
  ≥65 14 24
Pathological type     
  Squamous 17 23 5.268 0.072
  Adenocarcinoma 18 51
  Other types 6 5
T stage     
  T1 3 7 2.371 0.499
  T2 17 23
  T3 6 10
  T4 15 39
N stage     
  N0 3 5 2.631# 0.444
  N1 2 10
  N2 14 31
  N3 22 33
GTV (cm3) 23.64 ~ 892.00 (204.91) 16.55 ~ 617.50 (160.51) 1.108* 0.171
Chemotherapy     
  2-3 cycles 23 23 8.314 0.004
  4-5 cycles 18 56
  Range (median) 2-4 (3) 2-5 (4)   
Organ metastases     
  Single organ 27 54 0.077 0.781
  Multi-organ 14 25
Treatment response of primary tumor     
  CR 1 10 3.961 0.138
  PR 32 59
  NC 8 10
  1. Note: *Student t-test; GTV from a minimum–maximal value (median); #Fisher’s exact test.
\